Effectiveness and Safety of Dupilumab for Prurigo Nodularis in China: A Multicentric and Observational Study
Allergy · 2025
DOI: 10.1111/all.16478 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Allergy, 2025. Verfasst von Zuotao Zhao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Prurigo. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China (Grant number 82473512).
Abstract (Originalsprache)
Background
The efficacy and safety of dupilumab in patients with refractory prurigo nodularis (PN) is well established in clinical trials, but there is a lack of multicenter data regarding its effectiveness and safety in real‐world settings.
Methods
Patients with moderate‐to‐severe PN who initiated dupilumab treatment between July 2023 and January 2024, with a follow‐up period of at least 16 weeks at 10 hospitals in China were included. We used peak pruritus numeric rating scale (PP‐NRS), investigator global assessment (IGA) for PN, and dermatology life quality index for adults or children (DLQI/CDLQI) to assess disease control status and quality of life impairment, and monitored adverse events to assess the safety.
Results
A total of 73 PN patients (33 female, 40 male; mean age 45.9 ± 21.5 years) were included. A clinically meaningful improvement of ≥ 4 points in PP‐NRS (PP‐NRS4) was achieved in 84.9% of patients at Week 12. The percentage of patients achieving IGA 0/1 significantly increasing from 0% to 37.0% and 46.6% at Week 12 and 16, respectively. Patient‐reported quality of life outcomes showed substantial improvement, with decreasing from 16.6 ± 6.8 at baseline to 7.2 ± 4.9 at Week 12, 6.4 ± 4.5 at Week 16. The safety profile of dupilumab was favorable, with one patient reporting dry eyes.
Conclusion
Dupilumab can effectively improve the pruritus, nodular lesions and quality of life for PN in real‐world settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
- Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
- Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.
- National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
- NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, China.
- Department of Dermatology and Venerology, General Hospital of Ningxia Medical University, Yinchuan, China.
ORCID-Profile: Zuotao Zhao, Xiaoting Song, Jie Li
Förderung
- National Natural Science Foundation of China (Grant number 82473512)
Zitieren
APA
Zhao, Z., Song, X., Shang, Y., Liu, L., Zheng, R., Xia, J., Liu, Q., Hao, G., Li, J., Geng, S., An, J., Wang, Q., Liu, X., Tang, J., Xiao, Y., & Zhang, L. (2025). Effectiveness and Safety of Dupilumab for Prurigo Nodularis in China: A Multicentric and Observational Study. Allergy. https://doi.org/10.1111/all.16478
Vancouver
Zhao Z, Song X, Shang Y, Liu L, Zheng R, Xia J, et al. Effectiveness and Safety of Dupilumab for Prurigo Nodularis in China: A Multicentric and Observational Study. Allergy. 2025. doi:10.1111/all.16478
BibTeX
@article{Zhao2025,
author = {Zhao, Zuotao and Song, Xiaoting and Shang, Yuanyuan and Liu, Lijuan and Zheng, Rui and Xia, Jianxin and Liu, Qiang and Hao, Guodong and Li, Jie and Geng, Songmei and An, Jingang and Wang, Qiang and Liu, Xiaoyan and Tang, Jianping and Xiao, Yizhu and Zhang, Litao},
title = {Effectiveness and Safety of Dupilumab for Prurigo Nodularis in China: A Multicentric and Observational Study},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16478}
}
EUVIMED